Signe Sørensen Torekov is lead investigator of new study
Associate Professor Signe Sørensen Torekov is the lead investigator of a new study from the University of Copenhagen, Hvidovre and Glostrup Hospital. The findings from the study shows that using the intestinal hormone GLP-1 in obesity treatment prevents the loss of bone mass otherwise frequently associated with major weight loss.
Rapid weight loss can lead to loss of bone mass and an increased risk of bone fractures, but new research shows that by treating obesity with the GLP-1 hormone it can help prevent the loss of bone mass in addition to having other positive effects on the formation of new bone and on blood sugar levels.
Signe Sørensen Torekov from the Department of Biomedical Sciences and the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen is heading the study which has recently been published in the Journal of Clinical Endocrinology and Metabolism and was presented at the major international conference ‘American Diabetes Association’ (ADA) in Boston 6 June 2015.